## **Update on Herpes Zoster**

ACIP Meeting June 25, 2015

#### Rafael Harpaz, MD, MPH

CDC Lead, Zoster Working Group National Center for Immunizations and Respiratory Diseases Centers for Disease Control and Prevention



National Center for Immunization & Respiratory Diseases

Division of Viral Diseases

# Outline

- Clinical manifestations
- Epidemiology
- Zoster vaccine
- More recent policy developments
- Zoster vaccine uptake

# **Clinical Manifestations**







#### Letter from Patient with PHN:


"Doctor, I sure hope you can help me with this pain, it is so bad it has changed my whole life. I am unable to do any of the things I used to do."

## Herpes Zoster Ophthalmicus (HZO)




Courtesy of MN Oxman UCSD/San Diego VAMC

# **Epidemiology of HZ**



Marketscan administrative data, Insinga et al., J Gen Intern Med. 2005, 20:748-53.




PHN = 90 days of pain.

Olmsted County, MN, Yawn, et al., Mayo Clin Proc. 2007; 82:1341-9.

#### Epidemiology of HZ in U.S.

- Annual rate ~4 per 1000 population per year
- About 1 million cases in the U.S. annually
- Lifetime risk of developing HZ: about 30%
- Age-adjusted rates appear to be increasing

## **Epidemiology of HZ in U.S.**




Hales, Annals of Internal Medicine, 2013 159:739


## **Zoster Vaccine**

Licensed 2006 based on Shingles Prevention Study (SPS)
>38,500 healthy adults ≥60, followed ~3 years
Attenuated OKA-strain VZV (≥14X titer in Varivax)
Vaccine efficacy: 51% vs. HZ, 67% vs. PHN
No serious adverse events (local reactions common)
ACIP recommendation: 1 dose to adults ≥60 years
Results supported by subsequent observational studies

## SPS: Vaccine Efficacy by Age – HZ & PHN



## SPS: Vaccine Efficacy vs. PHN of Varying Duration




## **More Recent Developments**

- Clinical trial of adults 50-59: vaccine efficacy vs. HZ 70%,
  Zostavax licensed for adults 50-59 in 2011
- Follow up of original SPS-cohort to assess durability:
  - Effectiveness at 7-11 years reported as 21%, but study was not blinded, had modest precision, and lacked controls
- Second dose study: immunogenicity ≥10 years after 1<sup>st</sup> dose, compared to an initial dose in age-matched adults ≥70
  - Immunogenicity outcomes comparable in 2 arms, but these outcomes do not adequately predict protection

#### **More Recent Developments**

- ACIP recommendations are unchanged: 1 dose of zoster vaccine routinely recommended for adults ≥60 years
- "Programmatic conservatism" given that:
  HZ burden increases markedly with age
  Duration of vaccine protection uncertain
  Degree of protection provided by a 2<sup>nd</sup> dose uncertain

## **Zoster Vaccine Uptake**



\* 2007: National immunization Survey (Lu et al, Vaccine 27:882-7); 2008-13: NHIS (Am J Prev Med 40:e1-6 & unpublished)

#### **Zoster Vaccine Uptake**

Why has uptake been sluggish?

- Price
- Storage & handling (frozen vaccine)
- Supply shortages (resolved)
- Medicare Part D reimbursement
- Lowered prioritization of adult vaccines
- General fragmentation of preventive care for seniors

# Thank You!!!

